Anti-GRAK/ GZMK/ TRYP2 functional antibody
Anti-GRAK/ GZMK/ TRYP2 functional antibody for cell culture, ELISA & in-vivo assay
Go to GZMK/GZMK products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-SE0254-Ab-1/ GM-Tg-hg-SE0254-Ab-2 | Anti-Human GZMK monoclonal antibody | Human |
GM-Tg-rg-SE0254-Ab-1/ GM-Tg-rg-SE0254-Ab-2 | Anti-Rat GZMK monoclonal antibody | Rat |
GM-Tg-mg-SE0254-Ab-1/ GM-Tg-mg-SE0254-Ab-2 | Anti-Mouse GZMK monoclonal antibody | Mouse |
GM-Tg-cynog-SE0254-Ab-1/ GM-Tg-cynog-SE0254-Ab-2 | Anti-Cynomolgus/ Rhesus macaque GZMK monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-SE0254-Ab-1/ GM-Tg-felg-SE0254-Ab-2 | Anti-Feline GZMK monoclonal antibody | Feline |
GM-Tg-cang-SE0254-Ab-1/ GM-Tg-cang-SE0254-Ab-2 | Anti-Canine GZMK monoclonal antibody | Canine |
GM-Tg-bovg-SE0254-Ab-1/ GM-Tg-bovg-SE0254-Ab-2 | Anti-Bovine GZMK monoclonal antibody | Bovine |
GM-Tg-equg-SE0254-Ab-1/ GM-Tg-equg-SE0254-Ab-2 | Anti-Equine GZMK monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-SE0254-Ab-1/ GM-Tg-hg-SE0254-Ab-2; GM-Tg-rg-SE0254-Ab-1/ GM-Tg-rg-SE0254-Ab-2; GM-Tg-mg-SE0254-Ab-1/ GM-Tg-mg-SE0254-Ab-2; GM-Tg-cynog-SE0254-Ab-1/ GM-Tg-cynog-SE0254-Ab-2; GM-Tg-felg-SE0254-Ab-1/ GM-Tg-felg-SE0254-Ab-2; GM-Tg-cang-SE0254-Ab-1/ GM-Tg-cang-SE0254-Ab-2; GM-Tg-bovg-SE0254-Ab-1/ GM-Tg-bovg-SE0254-Ab-2; GM-Tg-equg-SE0254-Ab-1/ GM-Tg-equg-SE0254-Ab-2 |
Products Name | Anti-GZMK monoclonal antibody |
Format | mab |
Target Name | GZMK |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-GZMK benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-SE0254-Ag-1 | Recombinant multi-species GRAK/ GZMK/ TRYP2 protein |
ORF Viral Vector | vGMLP004549 | human GZMK Lentivirus particle |
ORF Viral Vector | pGMLP004549 | human GZMK Lentivirus plasmid |
ORF Viral Vector | pGMLPm004568 | mouse Gzmk Lentivirus plasmid |
ORF Viral Vector | vGMLPm004568 | mouse Gzmk Lentivirus particle |
Target information
Target ID | GM-SE0254 |
Target Name | GZMK |
Gene ID | 3003,14945,29165,705477,489200,101088984,528871,100052126 |
Gene Symbol and Synonyms | GZMK,TRYP2 |
Uniprot Accession | P49863,P49864 |
Uniprot Entry Name | GRAK_HUMAN,GRAK_RAT |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000113088 |
Target Classification | N/A |
The target: GZMK, gene name: GZMK, also named as TRYP2. This gene product is a member of a group of related serine proteases from the cytoplasmic granules of cytotoxic lymphocytes. Cytolytic T lymphocytes (CTL) and natural killer (NK) cells share the remarkable ability to recognize, bind, and lyse specific target cells. They are thought to protect their host by lysing cells bearing on their surface 'nonself' antigens, usually peptides or proteins resulting from infection by intracellular pathogens. The protein described here lacks consensus sequences for N-glycosylation present in other granzymes. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.